Pitfalls in the Interpretation of Pharmacoeconomic Studies Norman M. Kaplan Leading Article 13 November 2012 Pages: 303 - 305
Evaluation of Pharmaceutical Innovation Selwyn St LegerKathleen RowsellAlan Haycox Leading Article 13 November 2012 Pages: 306 - 311
Economic Costs of Functional Dyspepsia Olof NyrénGreger LindbergRein Seensalu Review Article 13 November 2012 Pages: 312 - 324
Economic Evaluation of Drug Therapy Magnus JohannessonPer-Olov JohanssonBengt Jönsson Review Article 13 November 2012 Pages: 325 - 337
Preference Based Outcome Measures for Economic Evaluation of Drug Interventions Abraham MehrezAmiram Gafni Review Article 13 November 2012 Pages: 338 - 345
A Comparison of the Costs and Benefits of Recombinant Human Erythropoietin (Epoetin) in the Treatment of Chronic Renal Failure in 5 European Countries Brenda LeeseJohn HuttonAlan Maynard Review Article 13 November 2012 Pages: 346 - 356
Comparison of the Cost-Effectiveness of Various Therapies for Common Prostatic Disorders Elizabeth A. AminMohammad Amin Review Article 13 November 2012 Pages: 357 - 369
Clinical Economics Catherine Copley-MerrimanLisa Egbuonu-DavisKati Copley-Merriman Original Research Article 13 November 2012 Pages: 370 - 376
Drug Cost Containment at a Large Teaching Hospital Peter I. PillansIan ConryBarbara E. Gie Original Research Article 13 November 2012 Pages: 377 - 382
Acceptable Usage of the Term ‘Cost-Effective’ Richard J. Grant Current Comment 13 November 2012 Pages: 383 - 384